- The PCORI Strategic Plan
- Our Programs
- Our Vision & Mission
- Financial Statements and Reports
- The PCORI Strategic Plan
- Board of Governors
- Methodology Committee
- Authorizing Law
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
- Draft Key Questions: Systematic Review of Audio Care for the Management of Mental Health and Chronic Conditions (2023)
- Patient-Centered Economic Outcomes Landscape (2023-2024)
Past Opportunities to Provide Input
- Proposed New Methodology Standards for Usual Care as a Comparator (2023)
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
Although new results from an ongoing PCORI-funded study into whether some patients with multiple sclerosis (MS) can safely stop taking certain kinds of medications as they age weren’t conclusive in either direction, the study’s lead researcher said the findings indicate that it is reasonable for some patients who have been on the medication for a long time to safely go off them.
John Corboy, MD—principal investigator on the DISCOMS trial, based at the University of Colorado in Aurora—presented the findings during the Consortium of Multiple Sclerosis Centers’ annual meeting in June 2022.
The special medications—known as disease-modifying therapies (DMT)—can reduce inflammation and nerve damage. However, DMTs are less effective at treating MS in its later phases. DMTs can also be difficult to take for a long time because they are costly, can cause a variety of side effects, and have long-term health risks.
The research team followed about 300 patients with MS, ages 55 and older, at nearly 20 MS centers nationwide. About half the participants kept taking their DMT, while the other half stopped taking the drugs.
While the study findings were not conclusive in either group, they have the potential to inform future practice and guide patients and their doctors with shared decision making. Further, discontinuation may be an appropriate choice for some older individuals with stable MS, resulting in potentially reducing the financial burden on patients taking DMT and the incidence of side effects often associated with the treatment.
Posted: July 7, 2022
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.